Antibody-Drug Conjugate and ATR Inhibitor Combination Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, including anti-TROP2 antibody-drug conjugates like datopotamab deruxtecan, face challenges in achieving enhanced efficacy, durability of therapeutic response, and reduced dose-dependent toxicity, especially in tumors resistant to PARP inhibitors.
Innovation Solution
The combination of an anti-TROP2 antibody-drug conjugate with an ATR inhibitor, such as AZD6738, to enhance antitumor efficacy by inhibiting DNA damage response and improving treatment outcomes in various cancer types.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-TROP2 antibody-drug conjugate is administered to treat cancer, then antitumor efficacy is improved, but dose-dependent toxicity increases
Solution Approach 1:
The patent combines anti-TROP2 antibody-drug conjugate with ATR inhibitor in a combination therapy regimen. This merging of two different therapeutic mechanisms allows for enhanced antitumor efficacy through multiple pathways of action while potentially reducing the dose of each individual agent required, thereby mitigating dose-dependent toxicity of the antibody-drug conjugate.
2Reliability
If anti-TROP2 antibody-drug conjugate is administered to treat cancer, then therapeutic response is achieved, but durability of response is insufficient
Solution Approach 1:
The combination therapy merges the cytotoxic action of the antibody-drug conjugate with the DNA damage response inhibition of the ATR inhibitor. This dual mechanism approach targets cancer cells through multiple pathways, potentially preventing resistance development and extending the durability of therapeutic response beyond what either agent achieves alone.
3Reliability
If ATR inhibitor is added to enhance antitumor efficacy, then therapeutic potential is improved, but treatment complexity increases
Solution Approach 1:
The patent integrates the ATR inhibitor with the existing antibody-drug conjugate regimen in a coordinated combination therapy. This merging approach enhances therapeutic potential by targeting complementary pathways in cancer cell death while managing treatment complexity through established combination therapy protocols and sequential administration strategies.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This combination therapy demonstrates superior antitumor effects, including enhanced efficacy, increased durability of response, and reduced toxicity, making it an effective approach for treating cancers resistant to previous treatments.
Implementation Method 1
ATR (ataxia telangiectasia and rad3-related kinase) is a serine/threonine protein kinase and member of the phosphatidylinositol 3-kinase related kinase (PIKK) family. During normal DNA replication, ATR is recruited at stalled replication forks, which can progress to double strand breaks if left unrepaired.
Implementation Method 2
Antibody-drug conjugates (ADCs), which are composed of a cytotoxic drug conjugated to an antibody, can deliver the drug selectively to cancer cells and can thus be expected to cause accumulation of the drug within cancer cells
Implementation Method 3
By inhibiting the DNA damage response to replication stress and double strand breaks introduced by the antibody-drug conjugate of the present disclosure, an ATR inhibitor may further enhance antitumor efficacy when administered in combination with the antibody-drug conjugate
Data Source
AI summary
A pharmaceutical product for administration of an anti TROP2 antibody-drug conjugate in combination with an ATR inhibitor is provided. The anti-TROP2 antibody-drug conjugate is an antibody-drug conjugate in which a drug linker represented by the following formula (wherein A represents the connecting position to an anti-TROP2 antibody) is conjugated to an anti-TROP2 antibody via a thioether bond. Also provided is a therapeutic use and method wherein the anti-TROP2 antibody-drug conjugate and the ATR inhibitor are administered in combination to a subject: Formula (I).